FSSAI Issues Notices to Nestlé and Zydus Wellness Over Nutritional Claims

The concrete rupture unfolded when the Food Safety and Standards Authority of India (FSSAI) dispatched official notices to Nestlé and Zydus Wellness, accusing them of misleading claims surrounding Complan, Lactogen, and Nan formulas. The regulator’s intervention targets specific assertions that the products enhance growth and immunity beyond what scientific evidence supports. By invoking the provisions of the Food Safety and Standards Act, the agency signaled a willingness to enforce stricter compliance, thereby unsettling the promotional strategies of two of the nation’s most visible consumer‑goods firms.

Underlying tension resides in the broader contest between corporate marketing ambitions and public health safeguards. The infant nutrition segment has long been a battleground for claims that straddle the line between beneficial guidance and exaggerated promises. The FSSAI’s move reflects mounting pressure from consumer advocacy groups and a governmental resolve to tighten oversight, especially as India grapples with malnutrition and the need for transparent nutritional information.

Downstream casualties will likely be felt by retailers, who must adjust shelf displays and promotional materials, and by parents who rely on clear labeling to make feeding choices. The two companies may face reduced sales volumes, potential recalls, and a wave of litigation that could reverberate across the sector. In the longer term, the episode may catalyze a revision of labeling norms, compelling all manufacturers to adopt more evidence‑based claims.